Skip to main content
Fig. 5 | Experimental Hematology & Oncology

Fig. 5

From: The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Fig. 5

Significance of MDSC populations in peripheral blood. a The changes of MDSC levels pre- and post-treatment of DC-CTL/CIK therapy in each nine patient (cohort 3). b The histogram showed the percentage of Treg cells and MDSC cells in cohort three patients pre-therapy and post-treatment. *Statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001)

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us